Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reiterates Neutral Rating for Perficient with Increased Price Target

Elaine Mendonca by Elaine Mendonca
February 29, 2024
in Breaking News
0
The Rise of Liquid Staking: How Validator-Specific Tokens Are Reshaping DeFi
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

On February 28, 2024, Puneet Jain, an analyst at JP Morgan, reiterated a Neutral rating for Perficient (NASDAQ: PRFT) while increasing the price target from $68 to $71. This adjustment signifies a more optimistic view on the company’s future performance.

_____

Various analysts have offered different price targets for Perficient, with the consensus suggesting a Hold sentiment. Looking ahead, there is a moderate upside potential for Perficient’s stock in the upcoming months.

Perficient Inc. (PRFT) Stock Price Drops 5.46% on February 28, 2024: Analysis and Outlook

On February 28, 2024, Perficient Inc. (PRFT) experienced a significant drop in its stock price, closing at $64.44. This marks a $3.72 decrease from the previous market close, representing a 5.46% decline in value.

One notable aspect of PRFT’s performance on this day is its position relative to its 52-week range and its 200-day simple moving average. According to data from CNN Money, PRFT is currently trading near the bottom of its 52-week range and below its 200-day moving average. This suggests that the stock may be experiencing some downward momentum and facing challenges in maintaining its value.

Despite the drop in price during regular trading hours, PRFT’s stock remained unchanged in after-hours trading. This could indicate that investors are taking a wait-and-see approach, unsure of how the stock will perform in the near future.

Overall, PRFT’s performance on February 28, 2024, reflects a day of decline for the company’s stock. Investors will likely be monitoring future developments and market trends to gauge whether PRFT can regain its value and reverse its downward momentum.

PRFT Stock Performance Review: Total Revenue, Net Income, and Earnings Per Share Remain Flat in 2024

On February 28, 2024, PRFT stock had a mixed performance as the company’s total revenue, net income, and earnings per share remained relatively flat compared to the previous year and quarter. According to data from CNN Money, PRFT reported a total revenue of $906.54 million for the past year, which was the same as the previous year. The total revenue for the fourth quarter was $220.79 million, also holding flat compared to the previous quarter. Similarly, PRFT’s net income for the past year was $98.93 million, showing a decrease of 5.23% compared to the previous year. The net income for the fourth quarter was $23.18 million, which remained flat compared to the previous quarter. Furthermore, PRFT reported earnings per share of $2.76 for the past year, which was a decrease of 5.11% compared to the previous year. The earnings per share for the fourth quarter was $0.65, holding flat compared to the previous quarter. Overall, PRFT stock performances on February 28, 2024, showed that the company’s financial metrics remained relatively flat compared to the previous year and quarter. Investors may want to closely monitor PRFT’s future earnings reports to see if there are any signs of growth or improvement in the company’s financial performance.

Tags: PRFT
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Business (1)

RBC Capital Analyst Affirms Outperform Rating on Archrock and Raises Price Target

Biotechnology Markets and money

uniQures Q4 Earnings Report A Closer Look at Financial Performance

Telecommunications Industry stock Trading

Analyst Reaffirms Positive Outlook on American Tower with Adjusted Price Target

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com